U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Thank you for reading Nation.Africa Show plans Gilead Sciences says it still plans to supply its twice-yearly injection for ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

The administration of Donald Trump has reportedly terminated funding for several HIV vaccine research programs.

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

O'Day said Gilead continues to discuss with government officials the importance of support for programs to diagnose HIV infection and link people to care. "The information we are getting is that ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...